Judy Chou

President and Chief Executive Officer at AltruBio

Dr. Judy Chou is the CEO and President of AltruBio, Inc. which is a clinical stage biotech company in San Francisco, CA. Before taking on her current roles, she headed the global Biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayer’s biotechnology pipeline, product portfolio over 3+ billion net revenue & 2000+ employees.

She is well recognized by the biomedical industry for her leadership and has received the Most Influential Women in Business Award in 2018 by San Francisco Business Times.

Before Bayer, Dr. Chou held the role of Vice President of Pharmaceutical Operations at Pfizer, Inc. She was also Vice President of R&D and Manufacturing at Tanvex Biopharma and has enabled the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in drug development and multiple filings of BLAs, NDAs, and INDs of novel products and is broadly recognized for her work at Medivation, Genentech, Pfizer (Wyeth) and Abbvie (Abbott) especially in the development of breakthrough technologies and accelerated product development.

Currently, Dr. Chou also serves as the Board of Directors of Akero Therapeutics, Inc. (NASDAQ: AKRO) and California Institute of Regenerative Medicines (CIRM); and the Advisory Board members of UC Berkeley Engineering School and Silicon Valley Women in Engineering. Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany